A study found that von Hippel-Lindau (VHL)-mutated RCC tumors exhibited infiltration by NKp46+ cells and showed higher expression of the NKp30 and NKp46 receptors compared to VHL-wild type RCC tumors, which means that the increased expression of activating NK receptor ligands in VHL-mutated RCC tumors, alongside potential downregulation or loss of MHC class I molecules, indicates a promising approach to enhancing NK cell-mediated antitumor immunity (Trotta et al., 2018). The gene discussed is VHL; the disease is renal cell carcinoma.